1. Home
  2. ZURA vs MSBIP Comparison

ZURA vs MSBIP Comparison

Compare ZURA & MSBIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$3.66

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Logo Midland States Bancorp Inc.

MSBIP

Midland States Bancorp Inc.

HOLD

Current Price

$25.40

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZURA
MSBIP
Founded
2022
N/A
Country
United States
United States
Employees
40
861
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ZURA
MSBIP
Price
$3.66
$25.40
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
892.6K
2.2K
Earning Date
05-14-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$22.03
52 Week High
$7.25
$25.94

Technical Indicators

Market Signals
Indicator
ZURA
MSBIP
Relative Strength Index (RSI) 36.23 50.74
Support Level $3.25 $25.02
Resistance Level $4.12 $25.45
Average True Range (ATR) 0.25 0.08
MACD 0.01 -0.02
Stochastic Oscillator 33.62 77.98

Price Performance

Historical Comparison
ZURA
MSBIP

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About MSBIP Midland States Bancorp Inc.

Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.

Share on Social Networks: